BioCryst Appoints Helen Thackray, M.D., to Board of Directors
September 23 2019 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that
the company has appointed clinical rare disease expert, Helen
Thackray, M.D., FAAP, to its board of directors.
Dr. Thackray currently serves as chief medical
officer and senior vice president of clinical development at
GlycoMimetics, Inc., a clinical-stage biotechnology company
advancing a novel pipeline of orphan drug candidates to address
unmet needs for patients.
She joined GlycoMimetics in 2006, and leads
their orphan product, fast track, and breakthrough therapy programs
at all stages of development in rare diseases. Prior to
joining GlycoMimetics, Dr. Thackray was vice president of clinical
development at Biosynexus, and served for over a decade on the
research ethics review board of the National Center for Healthcare
Statistics, part of the Centers for Disease Control and Prevention
(CDC).
She is a board-certified pediatrician,
practicing and serving on the faculty of the Children’s National
Medical Center and George Washington University School of Medicine
and Health Sciences from 2000-2019. Dr. Thackray has authored
more than 60 peer-reviewed articles and presentations.
“Advocacy for patients, and for better
therapeutic options for those with rare diseases, has been my
central focus throughout my career. With a deep pipeline of
home-grown oral medicines for rare diseases, BioCryst is positioned
to deliver dramatic improvements for patient care. I am
excited to join BioCryst as the company makes the transition from
clinical to commercial with its first rare disease program,” Dr.
Thackray said.
“As a physician and chief medical officer, Helen
adds important, complementary and contemporary clinical rare
disease experience to our board as BioCryst prepares to launch oral
BCX7353 to patients next year, and advances our multiple clinical
rare disease programs,” said Robert Ingram, chairman of
BioCryst.
Dr. Thackray holds a Bachelor of Science degree
in biological sciences from Stanford University, and an M.D. from
the George Washington University School of Medicine and Health
Sciences. She completed her pediatric residency and chief
residency at Children’s National Medical Center, trained in medical
genetics at the National Human Genome Research Institute at the
National Institutes of Health, and is a Fellow of the American
Academy of Pediatrics (FAAP).
About BioCryst
Pharmaceuticals
BioCryst discovers novel, oral small-molecule
medicines that treat rare diseases in which significant unmet
medical needs exist and an enzyme plays a key role in the
biological pathway of the disease. BioCryst has several ongoing
development programs including BCX7353, an oral treatment for
hereditary angioedema; BCX9930, an oral Factor D inhibitor for the
treatment of complement-mediated diseases; galidesivir, a potential
treatment for Marburg virus disease and Yellow Fever, and a
preclinical program to develop oral ALK-2 inhibitors for the
treatment of fibrodysplasia ossificans progressiva. RAPIVAB®
(peramivir injection), a viral neuraminidase inhibitor for the
treatment of influenza, is BioCryst's first approved product and
has received regulatory approval in the U.S., Canada, Australia,
Japan, Taiwan, Korea and the European Union. Post-marketing
commitments for RAPIVAB are ongoing. For more information, please
visit the Company's website at www.BioCryst.com.
Forward-Looking Statements
This press release contains forward-looking
statements, including statements regarding future results,
performance or achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause
BioCryst’s actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking
statements. These statements reflect our current views with respect
to future events and are based on assumptions and are subject to
risks and uncertainties. Given these uncertainties, you should not
place undue reliance on these forward-looking statements. Some of
the factors that could affect the forward-looking statements
contained herein include: that developing any HAE product candidate
may take longer or may be more expensive than planned; that ongoing
and future preclinical and clinical development of BCX9930, BCX9250
and our HAE drug candidates (including APeX-S, APeX-J, and
the BCX9930 Phase 1) may not have positive results; that BioCryst
may not be able to enroll the required number of subjects in
planned clinical trials of product candidates; that the company may
not advance human clinical trials with product candidates as
expected; that the FDA, EMA, PMDA or other applicable regulatory
agency may require additional studies beyond the studies planned
for product candidates, or may not provide regulatory clearances
which may result in delay of planned clinical trials, or may impose
a clinical hold with respect to such product candidate, or withhold
market approval for product candidates; that actual financial
results may not be consistent with expectations, including that
2019 operating expenses and cash usage may not be within
management's expected ranges. Please refer to the documents
BioCryst files periodically with the Securities and Exchange
Commission, specifically BioCryst’s most recent Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on
Form 8-K, all of which identify important factors that could cause
the actual results to differ materially from those contained in
BioCryst’s projections and forward-looking statements.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024